Business Wire | Aug 6, 2020 08:40AM EDT

Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference

Aug. 06, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 06, 2020--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 9:00 AM ET. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCKTM is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005572/en/

CONTACT: Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc. jrobinson@deciphera.com 781-906-1112

CONTACT: Media: David Rosen Argot Partners David.Rosen@argotpartners.com 212-600-1902